Bionano Genomics Stock to Reverse Split on Monday, January 27th (NASDAQ:BNGO)

Shares of Bionano Genomics, Inc. (NASDAQ:BNGO) are set to reverse split on Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 24th.

Bionano Genomics Stock Down 28.7 %

Bionano Genomics stock traded down $0.05 during mid-day trading on Thursday, reaching $0.13. The company’s stock had a trading volume of 31,894,418 shares, compared to its average volume of 19,639,521. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. Bionano Genomics has a 12 month low of $0.13 and a 12 month high of $1.36. The business’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.37. The company has a market capitalization of $15.47 million, a price-to-earnings ratio of -0.06 and a beta of 2.22.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH downgraded Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.

Institutional Investors Weigh In On Bionano Genomics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Carret Asset Management LLC increased its holdings in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Bionano Genomics in the third quarter valued at $46,000. Geode Capital Management LLC increased its holdings in shares of Bionano Genomics by 47.3% in the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Bionano Genomics in the second quarter valued at about $1,138,000. 11.35% of the stock is owned by institutional investors.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.